首页 > 最新文献

Ophthalmology and Therapy最新文献

英文 中文
Changes of Aqueous Humor Cytokine and Chemokine Profiles in Femtosecond Laser-Assisted Cataract Surgery in Comparison to Conventional Phacoemulsification. 飞秒激光辅助白内障手术与常规超声乳化手术中房水细胞因子和趋化因子谱的变化。
IF 3.2 3区 医学 Q2 OPHTHALMOLOGY Pub Date : 2026-01-01 Epub Date: 2025-11-18 DOI: 10.1007/s40123-025-01272-2
Lizaveta Chychko, Victor A Augustin, Hyeck-Soo Son, Sonja K Schickhardt, Volker Daniel, Ramin Khoramnia, Gerd U Auffarth

Introduction: This study investigates the anterior chamber (AC) inflammation in the early postoperative period after femtosecond laser-assisted cataract surgery (FLACS) in comparison to conventional phacoemulsification (CPS) by quantifying inflammatory and oxidative stress mediators in aqueous humor and correlating findings with clinical data.

Methods: In this prospective single-center study, 80 patients with cataracts were enrolled. Aqueous humor samples were collected from AC after femtosecond laser pretreatment in the FLACS group (40 patients) and at the beginning of standard cataract surgery before the primary incision was created in the CPS group (40 patients, control group). Mediators of postoperative inflammation including TNF-α, VEGF, IL-2, IL-1 β, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12, GM-CSF, IFN-γ, CXCL5/ENA-78, FGF-basic, G-CSF, IL-1-α, IL-1-ra, IL-17, CCL2/MCP-1, CCL3/MIP-1a, CCL4/MIP-1b, TPO, TGF-β-1, TGF-β-2 and TGF-β-3 were measured using a multiplex array system. The differences between both groups were analyzed using Mann-Whitney U test.

Results: In the FLACS group, significantly higher concentrations of IL (interleukin)-4, FGF-basic (fibroblast growth factor) and TGF-ß2 (Transforming growth factor-beta 2) were detected compared to the CPS group. Conversely, IL-10 levels were significantly higher in the CPS group than in the FLACS group.

Conclusions: FLACS triggers a distinct cytokine and growth factor profile in the aqueous humor, including elevated levels of IL-4, IL-12, FGF-basic, and TGF-β2 and a reduction in anti-inflammatory IL-10, indicating a shift toward proinflammatory and fibrotic signaling. These molecular changes may underlie immune activation and tissue remodeling not apparent in clinical examination and highlight the need for further studies to evaluate their long-term clinical relevance.

前言:本研究通过量化房水中的炎症和氧化应激介质,并将结果与临床数据进行比较,探讨飞秒激光辅助白内障手术(FLACS)术后早期前房(AC)炎症与常规超声乳化手术(CPS)的关系。方法:在这项前瞻性单中心研究中,纳入了80例白内障患者。FLACS组(40例)在飞秒激光预处理后,在标准白内障手术开始前,CPS组(40例,对照组)收集AC房水样本。术后炎症介质包括TNF-α、VEGF、IL-2、IL-1 β、IL-4、IL-5、IL-6、IL-8、IL-10、IL-12、GM-CSF、IFN-γ、CXCL5/ENA-78、FGF-basic、G-CSF、IL-1-α、IL-1-ra、IL-17、CCL2/MCP-1、CCL3/MIP-1a、CCL4/MIP-1b、TPO、TGF-β-1、TGF-β-2、TGF-β-3。采用Mann-Whitney U检验分析两组间差异。结果:与CPS组相比,FLACS组检测到IL(白细胞介素)-4、fgf -碱性(成纤维细胞生长因子)和TGF-ß2(转化生长因子- β 2)浓度显著升高。相反,CPS组IL-10水平明显高于FLACS组。结论:FLACS触发房水中不同的细胞因子和生长因子谱,包括IL-4、IL-12、fgf -碱性和TGF-β2水平升高,抗炎IL-10水平降低,表明向促炎和纤维化信号传导转变。这些分子变化可能是免疫激活和组织重塑的基础,在临床检查中不明显,并强调需要进一步研究以评估其长期临床相关性。
{"title":"Changes of Aqueous Humor Cytokine and Chemokine Profiles in Femtosecond Laser-Assisted Cataract Surgery in Comparison to Conventional Phacoemulsification.","authors":"Lizaveta Chychko, Victor A Augustin, Hyeck-Soo Son, Sonja K Schickhardt, Volker Daniel, Ramin Khoramnia, Gerd U Auffarth","doi":"10.1007/s40123-025-01272-2","DOIUrl":"10.1007/s40123-025-01272-2","url":null,"abstract":"<p><strong>Introduction: </strong>This study investigates the anterior chamber (AC) inflammation in the early postoperative period after femtosecond laser-assisted cataract surgery (FLACS) in comparison to conventional phacoemulsification (CPS) by quantifying inflammatory and oxidative stress mediators in aqueous humor and correlating findings with clinical data.</p><p><strong>Methods: </strong>In this prospective single-center study, 80 patients with cataracts were enrolled. Aqueous humor samples were collected from AC after femtosecond laser pretreatment in the FLACS group (40 patients) and at the beginning of standard cataract surgery before the primary incision was created in the CPS group (40 patients, control group). Mediators of postoperative inflammation including TNF-α, VEGF, IL-2, IL-1 β, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12, GM-CSF, IFN-γ, CXCL5/ENA-78, FGF-basic, G-CSF, IL-1-α, IL-1-ra, IL-17, CCL2/MCP-1, CCL3/MIP-1a, CCL4/MIP-1b, TPO, TGF-β-1, TGF-β-2 and TGF-β-3 were measured using a multiplex array system. The differences between both groups were analyzed using Mann-Whitney U test.</p><p><strong>Results: </strong>In the FLACS group, significantly higher concentrations of IL (interleukin)-4, FGF-basic (fibroblast growth factor) and TGF-ß2 (Transforming growth factor-beta 2) were detected compared to the CPS group. Conversely, IL-10 levels were significantly higher in the CPS group than in the FLACS group.</p><p><strong>Conclusions: </strong>FLACS triggers a distinct cytokine and growth factor profile in the aqueous humor, including elevated levels of IL-4, IL-12, FGF-basic, and TGF-β2 and a reduction in anti-inflammatory IL-10, indicating a shift toward proinflammatory and fibrotic signaling. These molecular changes may underlie immune activation and tissue remodeling not apparent in clinical examination and highlight the need for further studies to evaluate their long-term clinical relevance.</p>","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":" ","pages":"339-350"},"PeriodicalIF":3.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12882892/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145541632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Atropine-Loaded Contact Lens Sustained-Release Systems: A Narrative Review for the New Frontier for Myopia Management. 含阿托品的隐形眼镜缓释系统:近视治疗新前沿的述评。
IF 3.2 3区 医学 Q2 OPHTHALMOLOGY Pub Date : 2026-01-01 Epub Date: 2025-11-18 DOI: 10.1007/s40123-025-01280-2
Yuhang Liu, Xiaohang Chen, Chenhao Zhu, Dong Wang, Aimin Zhang, Longqian Liu

Myopia, particularly high myopia, poses a significant global public health burden. While low-concentration atropine is effective in controlling myopia progression, its conventional eye drop formulation is hampered by low bioavailability, poor patient compliance, and side effects, driving the need for advanced delivery systems. This review explores the contact lens-based drug delivery platform as a promising strategy to overcome these limitations. It synthesizes current evidence on the global myopia prevalence, atropine's pharmacology, and clinical efficacy, with a detailed analysis of the design principles for atropine-eluting lenses-encompassing material selection, drug-loading techniques, release mechanisms, and performance evaluation. The review systematically argues the superiority of this sustained-release system over traditional eye drops and discusses the remaining technical challenges, safety considerations, and future directions. We infer that integrating sustained drug delivery into a vision-correction device represents a transformative frontier in myopia management and has the potential to enhance efficacy, improve adherence, and reshape treatment paradigms.

近视,特别是高度近视,对全球公共卫生造成重大负担。虽然低浓度阿托品在控制近视进展方面是有效的,但其传统滴眼液配方受到生物利用度低、患者依从性差和副作用的阻碍,推动了对先进给药系统的需求。这篇综述探讨了基于隐形眼镜的给药平台作为克服这些局限性的一个有前途的策略。本文综合了目前全球近视患病率、阿托品药理学和临床疗效的证据,并详细分析了阿托品洗脱镜片的设计原则,包括材料选择、载药技术、释放机制和性能评估。这篇综述系统地论证了这种缓释系统相对于传统滴眼液的优越性,并讨论了剩余的技术挑战、安全考虑和未来发展方向。我们推断,将持续给药整合到视力矫正装置中代表了近视管理的变革前沿,并有可能提高疗效,改善依从性,重塑治疗范式。
{"title":"Atropine-Loaded Contact Lens Sustained-Release Systems: A Narrative Review for the New Frontier for Myopia Management.","authors":"Yuhang Liu, Xiaohang Chen, Chenhao Zhu, Dong Wang, Aimin Zhang, Longqian Liu","doi":"10.1007/s40123-025-01280-2","DOIUrl":"10.1007/s40123-025-01280-2","url":null,"abstract":"<p><p>Myopia, particularly high myopia, poses a significant global public health burden. While low-concentration atropine is effective in controlling myopia progression, its conventional eye drop formulation is hampered by low bioavailability, poor patient compliance, and side effects, driving the need for advanced delivery systems. This review explores the contact lens-based drug delivery platform as a promising strategy to overcome these limitations. It synthesizes current evidence on the global myopia prevalence, atropine's pharmacology, and clinical efficacy, with a detailed analysis of the design principles for atropine-eluting lenses-encompassing material selection, drug-loading techniques, release mechanisms, and performance evaluation. The review systematically argues the superiority of this sustained-release system over traditional eye drops and discusses the remaining technical challenges, safety considerations, and future directions. We infer that integrating sustained drug delivery into a vision-correction device represents a transformative frontier in myopia management and has the potential to enhance efficacy, improve adherence, and reshape treatment paradigms.</p>","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":" ","pages":"63-83"},"PeriodicalIF":3.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12882915/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145541627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Use of Tacrolimus for the Treatment of Pediatric Noninfectious Uveitis. 他克莫司治疗儿童非感染性葡萄膜炎。
IF 3.2 3区 医学 Q2 OPHTHALMOLOGY Pub Date : 2026-01-01 Epub Date: 2025-11-23 DOI: 10.1007/s40123-025-01275-z
Ingrid Pan, Clara Lin, Alan G Palestine, Rebecca G Edwards Mayhew, Jennifer L Jung

Introduction: Pediatric patients with noninfectious uveitis refractory to standard therapies have limited options. Efficacy and safety of systemic tacrolimus, a calcineurin inhibitor used successfully in adult noninfectious uveitis as an adjuvant immunomodulatory treatment, was investigated in the pediatric population at our institution.

Methods: This was a retrospective chart review of patients ≤ 18 years old diagnosed with noninfectious uveitis who were intolerant to or failed conventional systemic immunosuppressants between January 2014 and June 2025 at a tertiary referral center. The primary outcome was treatment success, defined as two or more of the following: ≤ 0.5+ anterior chamber cell, ≤ 2 drops of topical steroids per day per eye, improvement or resolution of vitritis, macular edema, papillitis, and angiographic leakage without addition of systemic therapy at 6 and 12 months after tacrolimus initiation. Secondary outcomes included need for dose reduction or discontinuation owing to adverse effects. Descriptive statistics were used to analyze the data.

Results: Data from 11 patients, with median age of 10 years, were analyzed. Treatment success was achieved in 88.9% and 63.6% of patients at 6 and 12 months, respectively. Although seven patients experienced laboratory abnormalities, tacrolimus was not discontinued. An average tacrolimus dose of 0.16 mg/kg/day divided every 12 h achieved therapeutic tacrolimus levels. Median duration (range) of tacrolimus therapy was 24 months (4-93 months).

Conclusions: Tacrolimus may potentially be a well-tolerated, safe, and effective option for refractory cases of pediatric noninfectious uveitis.

对标准治疗难治的非感染性葡萄膜炎患儿选择有限。系统性他克莫司(一种钙调神经磷酸酶抑制剂,成功用于成人非感染性葡萄膜炎的辅助免疫调节治疗)的有效性和安全性在我们机构的儿科人群中进行了研究。方法:回顾性分析2014年1月至2025年6月在三级转诊中心诊断的≤18岁的非感染性葡萄膜炎患者,这些患者对常规全身免疫抑制剂不耐受或失败。主要结局是治疗成功,定义为以下两项或多项:≤0.5+前房细胞,每天≤2滴局部类固醇,玻璃炎,黄斑水肿,乳头炎和血管造影渗漏的改善或解决,在他克莫司开始6个月和12个月后不增加全身治疗。次要结局包括因不良反应需要减少剂量或停药。采用描述性统计对数据进行分析。结果:分析了11例患者的数据,中位年龄为10岁。在6个月和12个月时,治疗成功率分别为88.9%和63.6%。虽然有7名患者出现实验室异常,但他克莫司并未停药。他克莫司的平均剂量为0.16 mg/kg/天,每12小时一次,达到他克莫司治疗水平。他克莫司治疗的中位持续时间(范围)为24个月(4-93个月)。结论:他克莫司对于难治性儿童非感染性葡萄膜炎可能是一种耐受性良好、安全有效的选择。
{"title":"Use of Tacrolimus for the Treatment of Pediatric Noninfectious Uveitis.","authors":"Ingrid Pan, Clara Lin, Alan G Palestine, Rebecca G Edwards Mayhew, Jennifer L Jung","doi":"10.1007/s40123-025-01275-z","DOIUrl":"10.1007/s40123-025-01275-z","url":null,"abstract":"<p><strong>Introduction: </strong>Pediatric patients with noninfectious uveitis refractory to standard therapies have limited options. Efficacy and safety of systemic tacrolimus, a calcineurin inhibitor used successfully in adult noninfectious uveitis as an adjuvant immunomodulatory treatment, was investigated in the pediatric population at our institution.</p><p><strong>Methods: </strong>This was a retrospective chart review of patients ≤ 18 years old diagnosed with noninfectious uveitis who were intolerant to or failed conventional systemic immunosuppressants between January 2014 and June 2025 at a tertiary referral center. The primary outcome was treatment success, defined as two or more of the following: ≤ 0.5+ anterior chamber cell, ≤ 2 drops of topical steroids per day per eye, improvement or resolution of vitritis, macular edema, papillitis, and angiographic leakage without addition of systemic therapy at 6 and 12 months after tacrolimus initiation. Secondary outcomes included need for dose reduction or discontinuation owing to adverse effects. Descriptive statistics were used to analyze the data.</p><p><strong>Results: </strong>Data from 11 patients, with median age of 10 years, were analyzed. Treatment success was achieved in 88.9% and 63.6% of patients at 6 and 12 months, respectively. Although seven patients experienced laboratory abnormalities, tacrolimus was not discontinued. An average tacrolimus dose of 0.16 mg/kg/day divided every 12 h achieved therapeutic tacrolimus levels. Median duration (range) of tacrolimus therapy was 24 months (4-93 months).</p><p><strong>Conclusions: </strong>Tacrolimus may potentially be a well-tolerated, safe, and effective option for refractory cases of pediatric noninfectious uveitis.</p>","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":" ","pages":"457-465"},"PeriodicalIF":3.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12882903/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145588481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Response to: Letter to the Editor Regarding "Safety, Tolerability, and Short-Term Efficacy of Low-Level Light Therapy for Dry Age-Related Macular Degeneration". 关于“低强度光治疗干性老年性黄斑变性的安全性、耐受性和短期疗效”的致编辑信的回复。
IF 3.2 3区 医学 Q2 OPHTHALMOLOGY Pub Date : 2026-01-01 Epub Date: 2025-12-03 DOI: 10.1007/s40123-025-01274-0
Enrico Borrelli, Giulia Coco, Vincenzo Scorcia, Adriano Carnevali, Michele Reibaldi, Giuseppe Giannaccare
{"title":"A Response to: Letter to the Editor Regarding \"Safety, Tolerability, and Short-Term Efficacy of Low-Level Light Therapy for Dry Age-Related Macular Degeneration\".","authors":"Enrico Borrelli, Giulia Coco, Vincenzo Scorcia, Adriano Carnevali, Michele Reibaldi, Giuseppe Giannaccare","doi":"10.1007/s40123-025-01274-0","DOIUrl":"10.1007/s40123-025-01274-0","url":null,"abstract":"","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":" ","pages":"499-501"},"PeriodicalIF":3.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12882911/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145669239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tomographic Differences in Thin Corneas Following DMEK in Fuchs Dystrophy: A Case-Control Study. 富克斯营养不良患者DMEK后薄角膜的层析成像差异:一项病例对照研究。
IF 3.2 3区 医学 Q2 OPHTHALMOLOGY Pub Date : 2026-01-01 Epub Date: 2025-11-08 DOI: 10.1007/s40123-025-01260-6
Josep Torras-Sanvicens, Marc Figueras-Roca, Carlos Rocha-de-Losada, Inés Bourleau, Ariadna Garreta, Elena Millá-Griñó, Ricardo P Casaroli-Marano

Introduction: This study characterized the prevalence of thin corneas and identified tomographic patterns following Descemet membrane endothelial keratoplasty (DMEK) in patients with Fuchs endothelial corneal dystrophy (FECD).

Methods: We conducted a retrospective observational study at a tertiary referral center, including 88 eyes with FECD treated by DMEK and an age- and sex-matched control group. Tomographic parameters such as central corneal thickness (CCT), pachymetric progression indices including Belin-Ambrosio D index (BAD-D), and anterior corneal asymmetry indices were analyzed using Scheimpflug imaging (Pentacam HR). Statistical analyses were performed to compare the DMEK and control groups and to examine correlations between clinical characteristics and CCT values.

Results: At 1 year, the mean CCT in the DMEK group was 525 ± 36 µm, compared with 561 ± 32 µm in healthy controls (p < 0.001). Women were much more likely than men to have thin corneas (40% vs. 3.6% with CCT below 500 µm, p < 0.001) and higher BAD-D values (2.71 vs. 1.99, p = 0.007). In multivariate analysis, baseline CCT (β = -0.001, p < 0.001), age (β = -0.001, p = 0.032), and sex (β = 0.046, p < 0.001) were the strongest predictors of percentage pachymetric reduction, indicating that thicker preoperative corneas, older patients, and women experienced greater deswelling and thinner 1-year CCT. Postoperative endothelial cell density had no impact on pachymetry outcomes.

Conclusion: Patients with FECD undergoing DMEK often present with postoperative corneal thinning, particularly among women. Although the underlying cause is not fully understood, these findings suggest a potential link between chronic preoperative corneal edema and the likelihood of stromal remodeling. Further research is required to elucidate the mechanisms underlying this thinning phenomenon.

本研究描述了Fuchs内皮性角膜营养不良(FECD)患者薄角膜的患病率,并确定了Descemet膜内皮角膜移植术(DMEK)后的断层扫描模式。方法:我们在一家三级转诊中心进行了一项回顾性观察研究,包括88只接受DMEK治疗的FECD眼睛和一个年龄和性别匹配的对照组。采用Scheimpflug显像(Pentacam HR)分析角膜中央厚度(CCT)、角膜厚度进展指数(berlin - ambrosio D指数(BAD-D))和角膜前侧不对称指数等层析参数。进行统计学分析,比较DMEK组和对照组,并检查临床特征与CCT值之间的相关性。结果:1年后,DMEK组的平均CCT为525±36µm,而健康对照组为561±32µm (p结论:接受DMEK的FECD患者经常出现术后角膜变薄,尤其是女性。虽然根本原因尚不完全清楚,但这些发现表明慢性术前角膜水肿与基质重塑的可能性之间存在潜在联系。需要进一步的研究来阐明这种变薄现象背后的机制。
{"title":"Tomographic Differences in Thin Corneas Following DMEK in Fuchs Dystrophy: A Case-Control Study.","authors":"Josep Torras-Sanvicens, Marc Figueras-Roca, Carlos Rocha-de-Losada, Inés Bourleau, Ariadna Garreta, Elena Millá-Griñó, Ricardo P Casaroli-Marano","doi":"10.1007/s40123-025-01260-6","DOIUrl":"10.1007/s40123-025-01260-6","url":null,"abstract":"<p><strong>Introduction: </strong>This study characterized the prevalence of thin corneas and identified tomographic patterns following Descemet membrane endothelial keratoplasty (DMEK) in patients with Fuchs endothelial corneal dystrophy (FECD).</p><p><strong>Methods: </strong>We conducted a retrospective observational study at a tertiary referral center, including 88 eyes with FECD treated by DMEK and an age- and sex-matched control group. Tomographic parameters such as central corneal thickness (CCT), pachymetric progression indices including Belin-Ambrosio D index (BAD-D), and anterior corneal asymmetry indices were analyzed using Scheimpflug imaging (Pentacam HR). Statistical analyses were performed to compare the DMEK and control groups and to examine correlations between clinical characteristics and CCT values.</p><p><strong>Results: </strong>At 1 year, the mean CCT in the DMEK group was 525 ± 36 µm, compared with 561 ± 32 µm in healthy controls (p < 0.001). Women were much more likely than men to have thin corneas (40% vs. 3.6% with CCT below 500 µm, p < 0.001) and higher BAD-D values (2.71 vs. 1.99, p = 0.007). In multivariate analysis, baseline CCT (β = -0.001, p < 0.001), age (β = -0.001, p = 0.032), and sex (β = 0.046, p < 0.001) were the strongest predictors of percentage pachymetric reduction, indicating that thicker preoperative corneas, older patients, and women experienced greater deswelling and thinner 1-year CCT. Postoperative endothelial cell density had no impact on pachymetry outcomes.</p><p><strong>Conclusion: </strong>Patients with FECD undergoing DMEK often present with postoperative corneal thinning, particularly among women. Although the underlying cause is not fully understood, these findings suggest a potential link between chronic preoperative corneal edema and the likelihood of stromal remodeling. Further research is required to elucidate the mechanisms underlying this thinning phenomenon.</p>","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":" ","pages":"205-219"},"PeriodicalIF":3.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12882917/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145471471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Beyond Vision: Prospective Real-World Evaluation of Quality-of-Life and Caregiver Burden in Diabetic Macular Edema Treated with Fluocinolone Acetonide (Iluvien®). 超越视力:氟西诺酮(Iluvien®)治疗糖尿病性黄斑水肿患者的生活质量和照顾者负担的前瞻性真实世界评估
IF 3.2 3区 医学 Q2 OPHTHALMOLOGY Pub Date : 2026-01-01 Epub Date: 2025-11-14 DOI: 10.1007/s40123-025-01277-x
João Alves-Ambrósio, Pedro Cardoso Teixeira, Mariana Garcia, João Chibante-Pedro, Miguel Ruão

Introduction: Diabetic macular edema (DME) imposes a substantial clinical and psychosocial burden on patients and caregivers due to frequent visits and intravitreal treatments. The fluocinolone acetonide intravitreal implant (Iluvien®) offers sustained drug delivery for up to 3 years. We assessed its real-world impact on vision, macular anatomy, intraocular pressure (IOP), quality of life (QoL), and treatment burden, including caregiver impact.

Methods: Prospective, real-world observational study of 41 patients with previously treated DME. Assessments occurred at baseline and at 6, 12, 18, 24, and 30 months. Outcomes included best-corrected visual acuity (BCVA), central macular thickness (CMT), IOP, and National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) composite scores. Burden metrics included clinic visits per year and caregiver accompaniment/absenteeism.

Results: At baseline, mean BCVA was 0.42 ± 0.30 logMAR, CMT 415.8 ± 106.5 µm, IOP 16.6 ± 4.1 mmHg, and NEI VFQ-25 67.6 ± 16.4; 46.3% of patients required caregiver accompaniment, and 61% reported pre-injection anxiety (median duration 2 days). At last follow-up, mean BCVA improved to 0.29 ± 0.26 logMAR (≈+6-7 ETDRS letters; p < 0.001), CMT decreased to 368.1 ± 79.6 µm (p = 0.002), and IOP remained stable at 16.7 ± 4.1 mmHg. The NEI VFQ-25 increased to 77.0 ± 18.0, with a significant main effect of time (repeated-measures analysis of variance (ANOVA), p = 0.001; partial η2 = 0.675); improvements were evident by 6 months and sustained through 30 months (all comparisons p < 0.05). Clinic visits declined from 5.8 ± 1.6 to 3.7 ± 1.5 per year (p < 0.001).

Conclusions: In a prospective real-world setting, Iluvien was associated with durable improvements in vision, macular anatomy, and QoL, with stable IOP. Treatment reduced the frequency of clinic visits and procedures, alleviating patient burden and caregiver absenteeism. These findings support Iluvien as a patient-centered, long-acting therapy for chronic DME and motivate multicenter validation and health-economic studies that incorporate caregiver outcomes.

糖尿病性黄斑水肿(DME)由于频繁就诊和玻璃体内治疗,给患者和护理人员带来了巨大的临床和社会心理负担。氟西诺酮醋酸玻璃体内植入物(Iluvien®)提供长达3年的持续给药。我们评估了其对视力、黄斑解剖、眼内压(IOP)、生活质量(QoL)和治疗负担(包括护理人员影响)的实际影响。方法:对41例既往治疗过的DME患者进行前瞻性、现实世界观察性研究。在基线和6、12、18、24和30个月进行评估。结果包括最佳矫正视力(BCVA)、中央黄斑厚度(CMT)、IOP和美国国家眼科研究所视觉功能问卷-25 (NEI VFQ-25)综合评分。负担指标包括每年的诊所访问量和护理人员陪伴/缺勤。结果:基线时,平均BCVA为0.42±0.30 logMAR, CMT为415.8±106.5µm, IOP为16.6±4.1 mmHg, NEI VFQ-25为67.6±16.4;46.3%的患者需要护理人员陪同,61%的患者报告注射前焦虑(中位持续时间2天)。末次随访时,平均BCVA改善至0.29±0.26 logMAR(≈+6-7 ETDRS字母;p 2 = 0.675);结论:在预期的现实环境中,Iluvien与视力、黄斑解剖结构和生活质量的持久改善以及稳定的IOP相关。治疗减少了诊所访问和程序的频率,减轻了患者的负担和护理人员的缺勤。这些发现支持Iluvien作为一种以患者为中心的慢性二甲醚长效疗法,并激励多中心验证和纳入护理结果的健康经济研究。
{"title":"Beyond Vision: Prospective Real-World Evaluation of Quality-of-Life and Caregiver Burden in Diabetic Macular Edema Treated with Fluocinolone Acetonide (Iluvien<sup>®</sup>).","authors":"João Alves-Ambrósio, Pedro Cardoso Teixeira, Mariana Garcia, João Chibante-Pedro, Miguel Ruão","doi":"10.1007/s40123-025-01277-x","DOIUrl":"10.1007/s40123-025-01277-x","url":null,"abstract":"<p><strong>Introduction: </strong>Diabetic macular edema (DME) imposes a substantial clinical and psychosocial burden on patients and caregivers due to frequent visits and intravitreal treatments. The fluocinolone acetonide intravitreal implant (Iluvien<sup>®</sup>) offers sustained drug delivery for up to 3 years. We assessed its real-world impact on vision, macular anatomy, intraocular pressure (IOP), quality of life (QoL), and treatment burden, including caregiver impact.</p><p><strong>Methods: </strong>Prospective, real-world observational study of 41 patients with previously treated DME. Assessments occurred at baseline and at 6, 12, 18, 24, and 30 months. Outcomes included best-corrected visual acuity (BCVA), central macular thickness (CMT), IOP, and National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) composite scores. Burden metrics included clinic visits per year and caregiver accompaniment/absenteeism.</p><p><strong>Results: </strong>At baseline, mean BCVA was 0.42 ± 0.30 logMAR, CMT 415.8 ± 106.5 µm, IOP 16.6 ± 4.1 mmHg, and NEI VFQ-25 67.6 ± 16.4; 46.3% of patients required caregiver accompaniment, and 61% reported pre-injection anxiety (median duration 2 days). At last follow-up, mean BCVA improved to 0.29 ± 0.26 logMAR (≈+6-7 ETDRS letters; p < 0.001), CMT decreased to 368.1 ± 79.6 µm (p = 0.002), and IOP remained stable at 16.7 ± 4.1 mmHg. The NEI VFQ-25 increased to 77.0 ± 18.0, with a significant main effect of time (repeated-measures analysis of variance (ANOVA), p = 0.001; partial η<sup>2</sup> = 0.675); improvements were evident by 6 months and sustained through 30 months (all comparisons p < 0.05). Clinic visits declined from 5.8 ± 1.6 to 3.7 ± 1.5 per year (p < 0.001).</p><p><strong>Conclusions: </strong>In a prospective real-world setting, Iluvien was associated with durable improvements in vision, macular anatomy, and QoL, with stable IOP. Treatment reduced the frequency of clinic visits and procedures, alleviating patient burden and caregiver absenteeism. These findings support Iluvien as a patient-centered, long-acting therapy for chronic DME and motivate multicenter validation and health-economic studies that incorporate caregiver outcomes.</p>","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":" ","pages":"293-305"},"PeriodicalIF":3.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12882914/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145524199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Photobiomodulation Therapy with Low-Level Light in Chronic Central Serous Chorioretinopathy: A Pilot Study. 低强度光生物调节治疗慢性中枢性浆液性脉络膜视网膜病变:一项初步研究。
IF 3.2 3区 医学 Q2 OPHTHALMOLOGY Pub Date : 2026-01-01 Epub Date: 2025-11-07 DOI: 10.1007/s40123-025-01263-3
Claudio Iovino, Alba Chiara Termite, Giacomo Boscia, Carmela Sannace, Francesco Boscia, Giuseppe Giannaccare, Pasquale Viggiano

Introduction: The purpose of this study is to evaluate the anatomical and functional outcomes of photobiomodulation (PBM) in patients with chronic central serous chorioretinopathy (cCSC).

Methods: In this retrospective study, ten eyes from nine patients with cCSC were treated with PBM. All patients had persistent subretinal fluid (SRF) for ≥ 6 months and no history of prior laser therapy. PBM was delivered once a week for 4 weeks, then monthly for two additional months using a dual-wavelength (590 and 625 nm) protocol delivered through the eye-light® device. Anatomical and functional outcomes were assessed at baseline and 6 months through multimodal imaging and best-corrected visual acuity (BCVA).

Results: Mean patient age was 45.37 years. At 6 months, mean BCVA improved significantly from 67.12 (±4.96) to 77.87 (±7.77) ETDRS letters (p = 0.0053). SRF completely resolved in 70% of eyes, partially improved in 10%, and remained unchanged in 20%. Among five eyes with serous avascular pigment epithelial detachment (PED), two PEDs resolved, one partially regressed, and two were unchanged. No adverse events were reported.

Conclusions: PBM may be beneficial in improving retinal anatomy and visual function in cCSC, with an excellent safety profile. These findings support PBM as a promising noninvasive treatment modality in patients with cCSC. Prospective controlled trials are warranted to validate its efficacy and durability.

本研究的目的是评估光生物调节(PBM)在慢性中枢性浆液性脉络膜视网膜病变(cCSC)患者中的解剖和功能结果。方法:对9例cCSC患者的10只眼进行PBM治疗。所有患者均有持续视网膜下积液(SRF)≥6个月,且既往无激光治疗史。PBM每周递送一次,持续4周,然后每月递送两个月,使用双波长(590和625 nm)方案通过眼光®装置递送。在基线和6个月时通过多模态成像和最佳矫正视力(BCVA)评估解剖和功能结果。结果:患者平均年龄45.37岁。6个月时,平均BCVA从67.12(±4.96)个ETDRS字母显著改善至77.87(±7.77)个ETDRS字母(p = 0.0053)。70%的眼睛完全消除SRF, 10%的眼睛部分改善,20%的眼睛保持不变。在5只患有浆液性无血管色素上皮脱离(PED)的眼睛中,2只PED消退,1只部分消退,2只不变。无不良事件报告。结论:PBM可能有助于改善cCSC患者的视网膜解剖结构和视觉功能,并具有良好的安全性。这些发现支持PBM作为cCSC患者的一种有前途的无创治疗方式。有必要进行前瞻性对照试验以验证其有效性和持久性。
{"title":"Photobiomodulation Therapy with Low-Level Light in Chronic Central Serous Chorioretinopathy: A Pilot Study.","authors":"Claudio Iovino, Alba Chiara Termite, Giacomo Boscia, Carmela Sannace, Francesco Boscia, Giuseppe Giannaccare, Pasquale Viggiano","doi":"10.1007/s40123-025-01263-3","DOIUrl":"10.1007/s40123-025-01263-3","url":null,"abstract":"<p><strong>Introduction: </strong>The purpose of this study is to evaluate the anatomical and functional outcomes of photobiomodulation (PBM) in patients with chronic central serous chorioretinopathy (cCSC).</p><p><strong>Methods: </strong>In this retrospective study, ten eyes from nine patients with cCSC were treated with PBM. All patients had persistent subretinal fluid (SRF) for ≥ 6 months and no history of prior laser therapy. PBM was delivered once a week for 4 weeks, then monthly for two additional months using a dual-wavelength (590 and 625 nm) protocol delivered through the eye-light® device. Anatomical and functional outcomes were assessed at baseline and 6 months through multimodal imaging and best-corrected visual acuity (BCVA).</p><p><strong>Results: </strong>Mean patient age was 45.37 years. At 6 months, mean BCVA improved significantly from 67.12 (±4.96) to 77.87 (±7.77) ETDRS letters (p = 0.0053). SRF completely resolved in 70% of eyes, partially improved in 10%, and remained unchanged in 20%. Among five eyes with serous avascular pigment epithelial detachment (PED), two PEDs resolved, one partially regressed, and two were unchanged. No adverse events were reported.</p><p><strong>Conclusions: </strong>PBM may be beneficial in improving retinal anatomy and visual function in cCSC, with an excellent safety profile. These findings support PBM as a promising noninvasive treatment modality in patients with cCSC. Prospective controlled trials are warranted to validate its efficacy and durability.</p>","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":" ","pages":"193-203"},"PeriodicalIF":3.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12882886/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145458662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Attention Deficit Hyperactivity Disorder (ADHD) in Ophthalmologists: Opportunities and Challenges. 眼科医生的注意缺陷多动障碍(ADHD):机遇与挑战。
IF 3.2 3区 医学 Q2 OPHTHALMOLOGY Pub Date : 2026-01-01 Epub Date: 2025-11-27 DOI: 10.1007/s40123-025-01282-0
Antonia Peilober-Richardson, Rajesh Nair, Rosemary Tattersall, Lauren Gledhill, Shabnum Aslam, Tariq Aslam

Attention deficit hyperactivity disorder (ADHD) is a prevalent neurodevelopmental condition. As an ophthalmologist, having ADHD presents both unique opportunities and considerable challenges, with eye institutions such as the Royal College of Ophthalmologists and the General Medical Council recognizing having ADHD as a protected characteristic. In light of a significant lack of literature specific to ophthalmologists with ADHD, this commentary is written by an expert multidisciplinary panel of ophthalmologists, psychologists and pharmacists, drawing upon evidence from wider medical literature and applied to the field of ophthalmology. ADHD traits can have an important impact, both positive and negative, on ophthalmologists' professional functioning. Creativity, visual-spatial intelligence, the ability to hyperfocus, and intuitive pattern recognition are all powerful skills for a successful microsurgeon. Skills such as adaptability and lateral problem-solving also help with innovation and research in the field. Additionally, having a diverse workforce enhances patient engagement and rapport, and is optimal for serving a diverse population. However, there are specific features of the ophthalmic environment which can be challenging, such as sensory overload or rapid turnover of clinical tasks, while self-regulation difficulties, including time and task management, may impact clinical efficiency, organization, and personal professional development. Other ADHD features such as emotional dysregulation, rejection sensitivity, and "masking" behaviours increase the risk of burnout and having ADHD is associated with a higher risk of having mental health conditions. Targeted adjustments and strategies such as flexible work patterns, personalized action plans, targeted coaching, and improved awareness education for supervisors and colleagues can mitigate these barriers and maximize performance and wellbeing in ophthalmologists with ADHD. This is an important and underrecognized area that would benefit from a body of research to inform specific individual and institutional recommendations for supporting and maximizing the potential of ophthalmologists with ADHD.

注意缺陷多动障碍(ADHD)是一种普遍的神经发育疾病。作为一名眼科医生,患有多动症既带来了独特的机会,也带来了相当大的挑战,像皇家眼科学院和一般医学委员会这样的眼科机构承认患有多动症是一种受保护的特征。鉴于缺乏专门针对多动症眼科医生的文献,本评论由一个由眼科医生、心理学家和药剂师组成的多学科专家小组撰写,他们从更广泛的医学文献中吸取证据,并将其应用于眼科领域。注意缺陷多动障碍的特点对眼科医生的专业能力有积极和消极的重要影响。创造力、视觉空间智能、超聚焦能力和直觉模式识别能力都是成功的显微外科医生的强大技能。适应性和横向解决问题等技能也有助于该领域的创新和研究。此外,拥有多样化的员工队伍可以提高患者的参与度和融洽关系,是为多样化人群服务的最佳选择。然而,眼科环境的某些特点可能具有挑战性,例如感官过载或临床任务的快速周转,而自我调节困难,包括时间和任务管理,可能会影响临床效率,组织和个人专业发展。ADHD的其他特征,如情绪失调、排斥敏感性和“掩饰”行为,会增加倦怠的风险,患有ADHD的人患精神健康问题的风险更高。有针对性的调整和策略,如灵活的工作模式,个性化的行动计划,有针对性的指导,以及对主管和同事的意识教育,可以减轻这些障碍,最大限度地提高患有多动症的眼科医生的表现和福祉。这是一个重要但未被充分认识的领域,它将受益于一系列研究,为支持和最大限度地发挥患有ADHD的眼科医生的潜力提供具体的个人和机构建议。
{"title":"Attention Deficit Hyperactivity Disorder (ADHD) in Ophthalmologists: Opportunities and Challenges.","authors":"Antonia Peilober-Richardson, Rajesh Nair, Rosemary Tattersall, Lauren Gledhill, Shabnum Aslam, Tariq Aslam","doi":"10.1007/s40123-025-01282-0","DOIUrl":"10.1007/s40123-025-01282-0","url":null,"abstract":"<p><p>Attention deficit hyperactivity disorder (ADHD) is a prevalent neurodevelopmental condition. As an ophthalmologist, having ADHD presents both unique opportunities and considerable challenges, with eye institutions such as the Royal College of Ophthalmologists and the General Medical Council recognizing having ADHD as a protected characteristic. In light of a significant lack of literature specific to ophthalmologists with ADHD, this commentary is written by an expert multidisciplinary panel of ophthalmologists, psychologists and pharmacists, drawing upon evidence from wider medical literature and applied to the field of ophthalmology. ADHD traits can have an important impact, both positive and negative, on ophthalmologists' professional functioning. Creativity, visual-spatial intelligence, the ability to hyperfocus, and intuitive pattern recognition are all powerful skills for a successful microsurgeon. Skills such as adaptability and lateral problem-solving also help with innovation and research in the field. Additionally, having a diverse workforce enhances patient engagement and rapport, and is optimal for serving a diverse population. However, there are specific features of the ophthalmic environment which can be challenging, such as sensory overload or rapid turnover of clinical tasks, while self-regulation difficulties, including time and task management, may impact clinical efficiency, organization, and personal professional development. Other ADHD features such as emotional dysregulation, rejection sensitivity, and \"masking\" behaviours increase the risk of burnout and having ADHD is associated with a higher risk of having mental health conditions. Targeted adjustments and strategies such as flexible work patterns, personalized action plans, targeted coaching, and improved awareness education for supervisors and colleagues can mitigate these barriers and maximize performance and wellbeing in ophthalmologists with ADHD. This is an important and underrecognized area that would benefit from a body of research to inform specific individual and institutional recommendations for supporting and maximizing the potential of ophthalmologists with ADHD.</p>","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":" ","pages":"35-43"},"PeriodicalIF":3.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12882869/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145636323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction: Attention Deficit Hyperactivity Disorder (ADHD) in Ophthalmologists: Opportunities and Challenges. 更正:注意缺陷多动障碍(ADHD)在眼科医生:机遇和挑战。
IF 3.2 3区 医学 Q2 OPHTHALMOLOGY Pub Date : 2026-01-01 DOI: 10.1007/s40123-026-01318-z
Antonia Peilober-Richardson, Rajesh Nair, Rosemary Tattersall, Lauren Gledhill, Shabnum Aslam, Tariq Aslam
{"title":"Correction: Attention Deficit Hyperactivity Disorder (ADHD) in Ophthalmologists: Opportunities and Challenges.","authors":"Antonia Peilober-Richardson, Rajesh Nair, Rosemary Tattersall, Lauren Gledhill, Shabnum Aslam, Tariq Aslam","doi":"10.1007/s40123-026-01318-z","DOIUrl":"10.1007/s40123-026-01318-z","url":null,"abstract":"","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":" ","pages":"45"},"PeriodicalIF":3.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12882875/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146053193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Risk of Developing Ocular Involvement Among Behçet's Disease Patients Presenting with Mucocutaneous Involvement at Disease Onset: Data from the International AIDA Network Behçet's Disease Registry. 发病时表现为皮肤粘膜受累的behaperet病患者发生眼部受累的风险:来自国际AIDA网络behaperet疾病登记处的数据
IF 3.2 3区 医学 Q2 OPHTHALMOLOGY Pub Date : 2026-01-01 Epub Date: 2025-11-08 DOI: 10.1007/s40123-025-01258-0
Antonio Vitale, Valeria Caggiano, Jessica Sbalchiero, Giuseppe Lopalco, Gaafar Ragab, Silvana Guerriero, Ibrahim AlMaglouth, Abdurrahman Tufan, Roberto Giacomelli, Haner Direskeneli, Piero Ruscitti, Gülen Hatemi, Francesco Carubbi, Ezgi Deniz Batu, Seza Ozen, Jurgen Sota, Henrique Ayres Mayrink Giardini, Micol Frassi, Petros P Sfikakis, Federica Gatti, Claudia Ammoscato, Amina Maher, Ayman Abdel-Monem Ahmed Mahmoud, Rosanna Dammacco, Hamit Kucuk, Riza Can Kardas, Ibrahim Yahya Cakir, Fatma Alibaz Öner, Gizem Sevik, Martina Gentile, Alican Karakoc, Alessia Alunno, Hulya Ercan Emreol, Francesca Crisafulli, Katerina Laskari, Francesco Ciccia, Maissa Thabet, Naceur Feriel, Serena Bugatti, Alessandra Milanesi, Maria Sole Chimenti, Benedetta Monosi, Matteo Piga, Alberto Floris, Francesco Gavioli, Cecilia Beatrice Chighizola, José Hernández-Rodríguez, Marco Cattalini, Marcello Govoni, Ombretta Viapiana, Adele Civino, Daniela Opris-Belinski, Carla Gaggiano, Rosaria Talarico, Annachiara Alemanno, Annarita Giardina, Giacomo Emmi, Piercarlo Sarzi Puttini, Maria Cristina Maggio, Paola Parronchi, Piero Portincasa, Alejandra de-la-Torre, Laura Daniela Rodríguez-Camelo, Stefano Gentileschi, Angela Mauro, Gian Domenico Sebastiani, Alma Nunzia Olivieri, Ali Şahin, Donato Rigante, Emre Bilgin, Emanuela Del Giudice, Luciana Breda, Amato De Paulis, Alberto Lo Gullo, Şükran Erten, Samar Tharwat, Lampros Fotis, Armin Maier, Antonella Insalaco, Anastasios Karamanakos, Alessandro Conforti, Özgül Soysal Gündüz, Abdelhfeez Moshrif, Francesca Li Gobbi, Stefania Costi, Elena Bartoloni, Patrizia Barone, Serena Guiducci, Andrés Gonzáles-García, Inés Hernanz Rodriguez, Giovanni Conti, Annamaria Iagnocco, Fatos Önen, Sulaiman M Al-Mayouf, Didar Uçar, Alberto Balistreri, Bruno Frediani, Luca Cantarini, Claudia Fabiani

Introduction: Behçet's disease (BD) frequently arises with exclusively mucocutaneous involvement, but some patients will develop major organ involvement, including ocular inflammation. This study aims to assess the patients' demographic and clinical characteristics that may be associated with the development of ocular involvement in patients with BD with exclusively mucocutaneous involvement in the early stages.

Methods: Patients' data were collected in the International AutoInflammatory Disease Alliance (AIDA) Network registry dedicated to BD.

Results: A total of 328 patients with BD were enrolled, 36 (11%) of whom developed ocular involvement over time. The following variables were significantly associated with the development of ocular inflammation at binary logistic regression: positive family history for BD (OR 4.32, 95% CI 1.16-14.72, p = 0.02), Arab ethnicity (OR 3.6, 95% CI 1.3-9.9, p = 0.01), presence of major oral aphthous ulceration (OR 3.26, 95% CI 1.18-8.99, p = 0.02), pseudofolliculitis plus erythema nodosum (OR 4.58, 95% CI 1.33-15.7, p = 0.016); conversely, white patients/patients of European descent (OR 0.33, 95% CI 0.12-0.91, p = 0.03) and the presence of a low number (one to two) ulcers at genital aphthous flares (OR 0.002, 95% CI ~ 0-0.07, p = 0.0006) were protective against the occurrence of ocular inflammatory manifestations. Genital aphthosis with more than five concurrent ulcers was associated with eye involvement in Arab patients (OR 209.2, 95% CI 5.8-7497, p = 0.003).

Conclusions: Major oral aphthosis, genital aphthous attacks with more than five concurrent ulcers, erythema nodosum coexisting with pseudofolliculitis, a positive family history of BD, and Arab ethnicity are associated with a higher risk of ocular involvement when BD arises with the sole mucocutaneous involvement.

behet病(BD)的发病通常只累及皮肤粘膜,但一些患者会累及主要器官,包括眼部炎症。本研究旨在评估早期单纯皮肤粘膜受累双相障碍患者的人口统计学和临床特征,这些特征可能与眼受累的发展有关。方法:患者数据从国际自身炎症疾病联盟(AIDA)网络注册中心收集。结果:共纳入328例BD患者,其中36例(11%)随着时间的推移发生眼部受累。在二元logistic回归中,以下变量与眼部炎症的发生显著相关:BD阳性家族史(OR 4.32, 95% CI 1.16-14.72, p = 0.02)、阿拉伯民族(OR 3.6, 95% CI 1.3-9.9, p = 0.01)、口腔口腔溃疡(OR 3.26, 95% CI 1.18-8.99, p = 0.02)、假性毛囊炎合并结节性红斑(OR 4.58, 95% CI 1.33-15.7, p = 0.016);相反,白人患者/欧洲血统患者(OR 0.33, 95% CI 0.12-0.91, p = 0.03)和生殖器口疮耀斑处少量溃疡(1 - 2)的存在(OR 0.002, 95% CI ~ 0-0.07, p = 0.0006)对眼部炎症表现的发生具有保护作用。伴有5个以上并发溃疡的生殖器溃疡与阿拉伯患者眼部受损伤相关(OR 209.2, 95% CI 5.8-7497, p = 0.003)。结论:重度口腔溃疡、并发5个以上溃疡的生殖器溃疡、结节性红斑与假性毛囊炎共存、BD阳性家族史和阿拉伯种族与双相障碍并发足底粘膜累及时眼部累及的高风险相关。
{"title":"The Risk of Developing Ocular Involvement Among Behçet's Disease Patients Presenting with Mucocutaneous Involvement at Disease Onset: Data from the International AIDA Network Behçet's Disease Registry.","authors":"Antonio Vitale, Valeria Caggiano, Jessica Sbalchiero, Giuseppe Lopalco, Gaafar Ragab, Silvana Guerriero, Ibrahim AlMaglouth, Abdurrahman Tufan, Roberto Giacomelli, Haner Direskeneli, Piero Ruscitti, Gülen Hatemi, Francesco Carubbi, Ezgi Deniz Batu, Seza Ozen, Jurgen Sota, Henrique Ayres Mayrink Giardini, Micol Frassi, Petros P Sfikakis, Federica Gatti, Claudia Ammoscato, Amina Maher, Ayman Abdel-Monem Ahmed Mahmoud, Rosanna Dammacco, Hamit Kucuk, Riza Can Kardas, Ibrahim Yahya Cakir, Fatma Alibaz Öner, Gizem Sevik, Martina Gentile, Alican Karakoc, Alessia Alunno, Hulya Ercan Emreol, Francesca Crisafulli, Katerina Laskari, Francesco Ciccia, Maissa Thabet, Naceur Feriel, Serena Bugatti, Alessandra Milanesi, Maria Sole Chimenti, Benedetta Monosi, Matteo Piga, Alberto Floris, Francesco Gavioli, Cecilia Beatrice Chighizola, José Hernández-Rodríguez, Marco Cattalini, Marcello Govoni, Ombretta Viapiana, Adele Civino, Daniela Opris-Belinski, Carla Gaggiano, Rosaria Talarico, Annachiara Alemanno, Annarita Giardina, Giacomo Emmi, Piercarlo Sarzi Puttini, Maria Cristina Maggio, Paola Parronchi, Piero Portincasa, Alejandra de-la-Torre, Laura Daniela Rodríguez-Camelo, Stefano Gentileschi, Angela Mauro, Gian Domenico Sebastiani, Alma Nunzia Olivieri, Ali Şahin, Donato Rigante, Emre Bilgin, Emanuela Del Giudice, Luciana Breda, Amato De Paulis, Alberto Lo Gullo, Şükran Erten, Samar Tharwat, Lampros Fotis, Armin Maier, Antonella Insalaco, Anastasios Karamanakos, Alessandro Conforti, Özgül Soysal Gündüz, Abdelhfeez Moshrif, Francesca Li Gobbi, Stefania Costi, Elena Bartoloni, Patrizia Barone, Serena Guiducci, Andrés Gonzáles-García, Inés Hernanz Rodriguez, Giovanni Conti, Annamaria Iagnocco, Fatos Önen, Sulaiman M Al-Mayouf, Didar Uçar, Alberto Balistreri, Bruno Frediani, Luca Cantarini, Claudia Fabiani","doi":"10.1007/s40123-025-01258-0","DOIUrl":"10.1007/s40123-025-01258-0","url":null,"abstract":"<p><strong>Introduction: </strong>Behçet's disease (BD) frequently arises with exclusively mucocutaneous involvement, but some patients will develop major organ involvement, including ocular inflammation. This study aims to assess the patients' demographic and clinical characteristics that may be associated with the development of ocular involvement in patients with BD with exclusively mucocutaneous involvement in the early stages.</p><p><strong>Methods: </strong>Patients' data were collected in the International AutoInflammatory Disease Alliance (AIDA) Network registry dedicated to BD.</p><p><strong>Results: </strong>A total of 328 patients with BD were enrolled, 36 (11%) of whom developed ocular involvement over time. The following variables were significantly associated with the development of ocular inflammation at binary logistic regression: positive family history for BD (OR 4.32, 95% CI 1.16-14.72, p = 0.02), Arab ethnicity (OR 3.6, 95% CI 1.3-9.9, p = 0.01), presence of major oral aphthous ulceration (OR 3.26, 95% CI 1.18-8.99, p = 0.02), pseudofolliculitis plus erythema nodosum (OR 4.58, 95% CI 1.33-15.7, p = 0.016); conversely, white patients/patients of European descent (OR 0.33, 95% CI 0.12-0.91, p = 0.03) and the presence of a low number (one to two) ulcers at genital aphthous flares (OR 0.002, 95% CI ~ 0-0.07, p = 0.0006) were protective against the occurrence of ocular inflammatory manifestations. Genital aphthosis with more than five concurrent ulcers was associated with eye involvement in Arab patients (OR 209.2, 95% CI 5.8-7497, p = 0.003).</p><p><strong>Conclusions: </strong>Major oral aphthosis, genital aphthous attacks with more than five concurrent ulcers, erythema nodosum coexisting with pseudofolliculitis, a positive family history of BD, and Arab ethnicity are associated with a higher risk of ocular involvement when BD arises with the sole mucocutaneous involvement.</p>","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":" ","pages":"223-237"},"PeriodicalIF":3.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12882929/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145471518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Ophthalmology and Therapy
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1